You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: R

    PROJECT SUMMARYWhile modern HIV combination therapy has transformed HIV into a manageable chronic infection for many patientsHIV AIDS remains a formidable global epidemicDespite the effectiveness of combining drugs from different classesside effects and drug resistance remain serious concerns for these life long therapiesThusthere is an enduring need for novel HIV inhibitors with new mechanisms of ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV

    SBC: NAVIGEN, INC.            Topic: NIAID

    SUMMARY    HIV/AIDS remains a formidable global epidemic, with ~37 million people infected (including ~1.1 million in  the  US)  and  about  one  million  AIDS-­related  deaths  in  2017  (UNAIDS,  CDC).  Despite  the  efficacy  of  modern  combination  anti-­retroviral  therapy  (cART),  side  effects  and  drug  resistance  remain  serious  obstacle ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A new class of broad-spectrum antibacterials for treating MDR infections

    SBC: Curza Inc            Topic: NIAID

    Project Summary Cūrza is developing a new class of broad-spectrum antibiotic, with a focus on multidrug-resistant (MDR) Enterobacteriaceae. The CZ-02 program is directed towards compounds that bind to a unique site on the bacterial ribosome that is not targeted by existing antibiotics and is therefore not expected to encounter cross- resistance to other antibiotics used clinically. Inspired by a ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Implantable Myoelectric Recording Array for Control of Prostheses

    SBC: RIPPLE LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): The goal of this translational SBIR program is to create a small, implantable system for recording myoelectric signals from residual and reinnervated muscles of individuals with forearm and other amputations. The signals will be wirelessly coupled to an external receiver for controlling prostheses. Compared to conventional surface electrodes, this system will p ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Fluorescein for Sentinel Lymph Node Detection

    SBC: VESTAN INC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical development of a potent D-peptide RSV inhibitor

    SBC: NAVIGEN, INC.            Topic: NIAID

    PROJECT SUMMARYRespiratory syncytial virusRSVis the major cause of severe lower respiratory tract infections in children and infantsaffecting an estimatedmillion people and causing up todeaths worldwide per yearWHOIn the USyoung children andadults are hospitalized annually due to RSV infectionHigh risk adultsthe elderly and patients with chronic heart or lung diseaseexperience the highest RSV attr ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Stream Dx: Point of Care Cellular Enabled IoT Communication Hub for Improved Diagnosis, Monitoring, and Post-Treatment Evaluation of LUTS

    SBC: STREAM DX, INC            Topic: 400

    PROJECT SUMMARY / ABSTRACT - STREAM DX Lower urinary tract symptoms (LUTS) is one of the most common medical problems among older men – affecting 33% of men by the time they reach 50 years of age and 75% by the time they reach the age of 80. LUTS is a progressive disease that has been shown to significantly increase the risk of depression and reduce quality of life. Early detection, intervention ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. HARVESTING AUTOLOGOUS PLATELETS FOR WOUND HEALING

    SBC: Thrombodyne Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Improved understanding of the role of growth factors as biochemical mediators of wound healing has paved the way for a new family of bioactive therapeutic products to expedite wound healing. Delivery of growth factors ( recombinant or as autologous platelets) has emerged as a possible commercial opportunity for improving the clinical outcomes of soft, bone, and ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Protease resistant D peptide Inhibitors of Ebola Virus Entry

    SBC: NAVIGEN, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola virus causes highly lethal hemorrhagic fever in humans and non human primates Since the first outbreak in there have been over natural human outbreaks with an average mortality rate near There are no approved agents to prevent or treat Ebola infection Due to ease of dissemination high lethality and ability to cause widespread panic the ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government